Streptokinase Injection IP
Acute Myocardial Infarction: Less than 12 hours
Deep Venous Thrombosis: Less than 14 days
Acute Massive Pulmonary Embolism
Acute Arterial Thrombosis and Embolism
Clotting in Haemodialysis Shunts
*STREPTONASE-R should be administered as soon as possible after onset of symptoms of myocardial infarction. The greatest benefit in mortality reduction is achieved when Streptokinase is administered within the first 6 hours but substantial benefit has been demonstrated at up to 12 hours.
**Administered for up to 3 days. If possible an angiographic assessment should then be performed. If no clinical effect is noted after 3 days, treatment should be discontinued.
*** Follow-up Treatment: After every course of recombinant streptokinase therapy, a follow-up treatment with anticoagulants or platelet aggregation inhibitors can be instituted as a prevention of rethrombosis. With heparin therapy in particular an increased risk of haemoglobin must be considered.
STREPTONASE-R therapy may otherwise be continued for an additional 1-3 days if considered necessary.
We also deals in:
|Name of the Product||Composition|
|Streptonase-R 15||Recombinant Streptokinase 15LIU|
FC/B-1 (Extn.), Mohan Co-operative Industrial Estate, Mathura Road, New Delhi, Delhi, 110044, India